From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells.
breast cancer
endocrine resistance
estrogen receptor
lncRNA
microRNA
ncRNA
tamoxifen
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Jul 2021
22 Jul 2021
Historique:
received:
31
03
2021
revised:
03
07
2021
accepted:
15
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer mortality among women. Two thirds of patients are classified as hormone receptor positive, based on expression of estrogen receptor alpha (ERα), the main driver of breast cancer cell proliferation, and/or progesterone receptor, which is regulated by ERα. Despite presenting the best prognosis, these tumors can recur when patients acquire resistance to treatment by aromatase inhibitors or antiestrogen such as tamoxifen (Tam). The mechanisms that are involved in Tam resistance are complex and involve multiple signaling pathways. Recently, roles for microRNAs and lncRNAs in controlling ER expression and/or tamoxifen action have been described, but the underlying mechanisms are still little explored. In this review, we will discuss the current state of knowledge on the roles of microRNAs and lncRNAs in the main mechanisms of tamoxifen resistance in hormone receptor positive breast cancer. In the future, this knowledge can be used to identify patients at a greater risk of relapse due to the expression patterns of ncRNAs that impact response to Tam, in order to guide their treatment more efficiently and possibly to design therapeutic strategies to bypass mechanisms of resistance.
Identifiants
pubmed: 34359587
pii: cancers13153688
doi: 10.3390/cancers13153688
pmc: PMC8345104
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Oncogene. 2019 Jul;38(28):5551-5565
pubmed: 30967627
BMC Cancer. 2018 Aug 24;18(1):850
pubmed: 30143015
Am J Transl Res. 2015 Oct 15;7(10):2115-26
pubmed: 26692956
Int J Oncol. 2019 Mar;54(3):1033-1042
pubmed: 30628639
Mol Med Rep. 2018 Jul;18(1):1120-1126
pubmed: 29845295
BMC Cancer. 2016 Jul 04;16:378
pubmed: 27378269
J Biol Chem. 2017 Aug 18;292(33):13551-13564
pubmed: 28637868
PLoS Genet. 2013 Jun;9(6):e1003569
pubmed: 23818866
Breast Cancer Res Treat. 2019 Jun;175(2):353-368
pubmed: 30830488
Aging (Albany NY). 2020 Oct 24;12(20):20658-20683
pubmed: 33098638
Stem Cells. 2016 Aug;34(8):2052-62
pubmed: 27090862
Cancer Lett. 2017 Mar 1;388:230-238
pubmed: 27986463
J Biol Chem. 2008 Oct 31;283(44):29897-903
pubmed: 18708351
Cell Physiol Biochem. 2016;40(3-4):707-715
pubmed: 27898409
Biochem Biophys Res Commun. 2016 Sep 2;477(4):768-773
pubmed: 27363334
Int J Mol Med. 2020 Feb;45(2):497-509
pubmed: 31894257
Cell Physiol Biochem. 2018;51(4):1518-1532
pubmed: 30497079
Front Pharmacol. 2017 Dec 13;8:902
pubmed: 29326587
Cancer Res. 2008 Feb 1;68(3):852-60
pubmed: 18245487
Breast Cancer Res Treat. 2015 Jan;149(1):81-9
pubmed: 25503779
Cell Rep. 2020 Jun 9;31(10):107753
pubmed: 32521278
Nat Rev Cancer. 2009 Sep;9(9):631-43
pubmed: 19701242
Biomed Res Int. 2016;2016:8797206
pubmed: 27556043
Sci Rep. 2015 Mar 04;5:8735
pubmed: 25736597
Sci Rep. 2015 Aug 10;5:13170
pubmed: 26255816
Drug Des Devel Ther. 2021 Jan 22;15:245-257
pubmed: 33519190
Cell Oncol (Dordr). 2019 Oct;42(5):627-644
pubmed: 31115881
Breast Cancer. 2021 Jan;28(1):175-186
pubmed: 32865695
Aging (Albany NY). 2019 Aug 10;11(15):5705-5725
pubmed: 31400752
Oncol Lett. 2020 Nov;20(5):160
pubmed: 32934728
Ther Adv Med Oncol. 2017 May;9(5):335-346
pubmed: 28529550
Cancer Chemother Pharmacol. 2017 Feb;79(2):327-337
pubmed: 28063065
Biomed Pharmacother. 2016 Feb;77:37-44
pubmed: 26796263
Cell. 2010 Aug 6;142(3):409-19
pubmed: 20673990
Cancer Res. 2013 Nov 15;73(22):6554-62
pubmed: 24204025
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):716-21
pubmed: 18184812
Tumour Biol. 2017 Jun;39(6):1010428317705790
pubmed: 28635401
Nat Biotechnol. 2011 Nov 13;30(1):99-104
pubmed: 22081020
Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2838-2846
pubmed: 31002134
Oncogene. 2011 Feb 17;30(7):822-31
pubmed: 20956939
Oncol Rep. 2019 Mar;41(3):1901-1910
pubmed: 30747221
Eur Rev Med Pharmacol Sci. 2016 Oct;20(20):4362-4368
pubmed: 27831634
J Cancer. 2020 Mar 13;11(12):3416-3423
pubmed: 32284737
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Int J Mol Sci. 2019 Jan 14;20(2):
pubmed: 30646517
Oncogene. 2012 Jan 5;31(1):39-47
pubmed: 21666713
Nat Commun. 2016 Sep 26;7:12791
pubmed: 27666543
Onco Targets Ther. 2017 Sep 07;10:4369-4378
pubmed: 28919786
Cancer Lett. 2018 Oct 10;434:1-10
pubmed: 29969658
Cell Signal. 2020 Apr;68:109536
pubmed: 31927036
Cell Death Dis. 2016 Nov 3;7(11):e2454
pubmed: 27809310
Sci Rep. 2015 Jan 06;5:7641
pubmed: 25560734
Nat Rev Genet. 2020 Feb;21(2):102-117
pubmed: 31729473
Int J Cancer. 2019 Aug 1;145(3):842-856
pubmed: 30720865
Cell Rep. 2016 May 31;15(9):2025-37
pubmed: 27210747
Nature. 2012 Sep 6;489(7414):101-8
pubmed: 22955620
J Natl Cancer Inst. 2010 May 19;102(10):706-21
pubmed: 20388878
PLoS One. 2019 May 23;14(5):e0217181
pubmed: 31120927
Mol Cancer. 2017 Oct 17;16(1):161
pubmed: 29041978
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Exp Clin Cancer Res. 2019 Oct 10;38(1):414
pubmed: 31601253
Nat Genet. 2000 May;25(1):19-21
pubmed: 10802648
Cells. 2020 Jan 07;9(1):
pubmed: 31936122
Cancer Res. 2018 Sep 1;78(17):4915-4928
pubmed: 29945962
Cancer Med. 2018 Dec;7(12):6137-6146
pubmed: 30430768
Cancer Lett. 2009 Aug 8;280(2):184-91
pubmed: 19185986
Lancet. 2005 May 14-20;365(9472):1687-717
pubmed: 15894097
J Breast Cancer. 2017 Mar;20(1):35-44
pubmed: 28382093
Cancer Manag Res. 2020 Mar 10;12:1771-1777
pubmed: 32210618
Int J Mol Sci. 2016 Aug 19;17(8):
pubmed: 27548161
Biomed Pharmacother. 2018 Nov;107:117-128
pubmed: 30086458
J Biol Chem. 2008 Nov 7;283(45):31079-86
pubmed: 18790736
Oncotarget. 2016 Jul 5;7(27):42261-42273
pubmed: 27304060
J Hematol Oncol. 2019 Jul 24;12(1):81
pubmed: 31340867
BMC Cancer. 2015 Jul 24;15:540
pubmed: 26206152
Int J Cancer. 2003 Nov 10;107(3):353-8
pubmed: 14506733
Genome Res. 2012 Sep;22(9):1775-89
pubmed: 22955988
Nat Rev Cancer. 2011 Nov 24;11(12):849-64
pubmed: 22113163
Cell Rep. 2019 Jul 2;28(1):104-118.e8
pubmed: 31269432
PLoS One. 2016 Dec 15;11(12):e0168406
pubmed: 27977766
Nat Rev Endocrinol. 2011 Aug 16;7(12):715-26
pubmed: 21844907
Science. 2005 Sep 2;309(5740):1559-63
pubmed: 16141072
J Pathol. 2021 Jun;254(2):185-198
pubmed: 33638154
PLoS One. 2017 Feb 2;12(2):e0167969
pubmed: 28151938
Oncogene. 2015 Jul 23;34(30):3895-907
pubmed: 25531331
Cell. 2007 Jun 29;129(7):1311-23
pubmed: 17604720
Br J Cancer. 2004 May 17;90(10):1942-8
pubmed: 15138475
J Gene Med. 2019 Jan;21(1):e3065
pubmed: 30549380
Nature. 2010 Apr 15;464(7291):1071-6
pubmed: 20393566
Oncotarget. 2016 Sep 20;7(38):61166-61182
pubmed: 27533459
J Cell Physiol. 2019 Mar;234(3):2880-2894
pubmed: 30203615
Med Sci Monit. 2016 Oct 21;22:3860-3867
pubmed: 27765938
Horm Cancer. 2010 Dec;1(6):306-19
pubmed: 21761362
Int J Oncol. 2015 Jan;46(1):205-14
pubmed: 25333707
Breast. 2019 Feb;43:31-38
pubmed: 30415143
Cell Signal. 2018 Jan;42:165-175
pubmed: 28988130
Annu Rev Med. 2011;62:233-47
pubmed: 20887199
Prog Mol Biol Transl Sci. 2016;144:539-562
pubmed: 27865467
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:193-206
pubmed: 25917453
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
Cancer Biother Radiopharm. 2018 Aug;33(6):241-251
pubmed: 30048163
Oncotarget. 2015 Oct 13;6(31):31944-57
pubmed: 26397135
Mol Biol (Mosk). 2016 Sep-Oct;50(5):821-827
pubmed: 27830684
Front Oncol. 2015 Feb 16;5:24
pubmed: 25763354
Open Med (Wars). 2020 Dec 15;16(1):68-80
pubmed: 33385064
Mol Cancer. 2020 Feb 4;19(1):22
pubmed: 32019587
Biochem Biophys Res Commun. 2017 Feb 5;483(2):840-846
pubmed: 28063929
Cancer Gene Ther. 2010 Aug;17(8):523-31
pubmed: 20467450
Nucleic Acids Res. 2008 Jan;36(1):76-93
pubmed: 17986456
Clin Breast Cancer. 2017 Apr;17(2):79-90
pubmed: 27687476
Breast Cancer Res Treat. 2014 Jul;146(1):85-97
pubmed: 24906430
Nat Genet. 2011 Jun 05;43(7):621-9
pubmed: 21642992
Nat Commun. 2020 Nov 2;11(1):5513
pubmed: 33139730
Life Sci. 2016 Mar 15;149:104-13
pubmed: 26896688
J Pathol. 2010 May;221(1):3-12
pubmed: 20225336
Nat Rev Cancer. 2018 Jun;18(6):377-388
pubmed: 29662238
DNA Cell Biol. 2016 Sep;35(9):459-70
pubmed: 27213978
Mol Cell Biol. 2019 Nov 12;39(23):
pubmed: 31501276
Endocrinology. 2005 Dec;146(12):5474-84
pubmed: 16150902
Eur Rev Med Pharmacol Sci. 2017 Feb;21(4):706-714
pubmed: 28272713
Cancer Genomics Proteomics. 2017 Sep-Oct;14(5):299-313
pubmed: 28870998
Mol Med. 2011;17(11-12):1233-41
pubmed: 21826373
Eur Rev Med Pharmacol Sci. 2019 Feb;23(4):1563-1573
pubmed: 30840279
Oncotarget. 2016 Mar 22;7(12):13902-16
pubmed: 26418898
EMBO J. 2012 Feb 1;31(3):522-33
pubmed: 22193719
Cell Physiol Biochem. 2018;46(4):1643-1649
pubmed: 29694965
J Mol Biol. 2013 Oct 9;425(19):3707-22
pubmed: 23375982
Bioessays. 2002 Mar;24(3):244-54
pubmed: 11891761
Cancer Cell Int. 2021 Jan 15;21(1):55
pubmed: 33451320
Brief Bioinform. 2019 Mar 22;20(2):551-564
pubmed: 29697742
J Cell Biochem. 2019 Aug;120(8):12966-12976
pubmed: 31001849
Breast Cancer Res. 2012 Apr 04;14(2):R57
pubmed: 22475046
J Pathol. 2014 Aug;233(4):368-79
pubmed: 24752803
Mol Cell. 2011 Nov 18;44(4):667-78
pubmed: 21963238
Chin J Cancer. 2017 Jun 24;36(1):52
pubmed: 28646911
Front Cell Dev Biol. 2019 Oct 02;7:217
pubmed: 31632968
Clin Cancer Res. 1997 Jun;3(6):849-54
pubmed: 9815758
Mol Cancer. 2015 Dec 15;14:208
pubmed: 26666173
Mol Cancer. 2010 Dec 20;9:317
pubmed: 21172025
Development. 2013 Mar;140(6):1184-95
pubmed: 23444351
Onco Targets Ther. 2018 Nov 09;11:8001-8012
pubmed: 30519041
Cell Physiol Biochem. 2014;33(5):1557-67
pubmed: 24854844
Oncologist. 2018 May;23(5):528-539
pubmed: 29352052
Science. 2010 Aug 6;329(5992):689-93
pubmed: 20616235
J Mol Endocrinol. 2017 Jan;58(1):R15-R31
pubmed: 27729460
FASEB J. 2018 Feb;32(2):588-600
pubmed: 28939591
Nat Commun. 2021 Mar 19;12(1):1786
pubmed: 33741974
Front Endocrinol (Lausanne). 2020 Jul 31;11:506
pubmed: 32849292
Cancer Res. 2011 Apr 15;71(8):2926-37
pubmed: 21393507
Mol Endocrinol. 2007 Sep;21(9):2112-23
pubmed: 17550982
Oncotarget. 2017 Oct 6;8(59):99978-99989
pubmed: 29245954
Lancet. 2017 Mar 18;389(10074):1134-1150
pubmed: 27865536
Sci Rep. 2019 Jul 1;9(1):9430
pubmed: 31263129
J Natl Cancer Inst. 2018 Apr 1;110(4):
pubmed: 29028222
Mol Cell Endocrinol. 2011 Mar 1;334(1-2):76-82
pubmed: 21056084
Tumour Biol. 2016 Nov;37(11):14733-14743
pubmed: 27629141
Nat Commun. 2015 Jul 17;6:7769
pubmed: 26183061
J Drug Target. 2021 Aug;29(7):742-753
pubmed: 33472456
Nature. 2009 Mar 12;458(7235):223-7
pubmed: 19182780
Biochem J. 2018 Jun 11;475(11):1939-1954
pubmed: 29891531
Int J Oncol. 2021 Jan;58(1):33-44
pubmed: 33367930
Cancer Lett. 2011 Dec 26;313(1):26-43
pubmed: 21955614
Breast Cancer Res Treat. 2014 Sep;147(2):423-31
pubmed: 25007959
Biochemistry (Mosc). 2018 May;83(5):603-611
pubmed: 29738694
Biomed Pharmacother. 2019 Feb;110:400-408
pubmed: 30530042
Sci Rep. 2018 Oct 23;8(1):15670
pubmed: 30353135
J Breast Cancer. 2020 Jan 16;23(2):129-140
pubmed: 32395373
Cancer Discov. 2015 Sep;5(9):944-59
pubmed: 26180042
Cancer Treat Rev. 2012 Oct;38(6):698-707
pubmed: 22178455
Endocr Relat Cancer. 2004 Dec;11(4):643-58
pubmed: 15613444
Signal Transduct Target Ther. 2020 Jun 19;5(1):101
pubmed: 32561705
J Natl Cancer Inst. 2004 Jun 16;96(12):926-35
pubmed: 15199112
Int J Cancer. 2002 May 1;99(1):35-42
pubmed: 11948489
Science. 2012 Dec 14;338(6113):1469-72
pubmed: 23239737
Eur J Pharm Sci. 2018 Jul 30;120:73-88
pubmed: 29719240
Cell Biol Toxicol. 2017 Apr;33(2):183-195
pubmed: 27837347
Mol Cell Endocrinol. 2010 Jul 29;323(2):268-76
pubmed: 20302909
Front Oncol. 2017 Mar 15;7:26
pubmed: 28361033
Cell. 2013 Jul 3;154(1):240-51
pubmed: 23810193
Bioorg Chem. 2017 Apr;71:257-274
pubmed: 28274582
Int J Clin Exp Pathol. 2020 Oct 01;13(10):2455-2473
pubmed: 33165437
Sci Rep. 2020 Aug 24;10(1):14145
pubmed: 32839509
J Lipid Res. 2018 Dec;59(12):2297-2307
pubmed: 30315000
Nature. 2011 Aug 28;477(7364):295-300
pubmed: 21874018
Oncol Lett. 2018 Mar;15(3):3532-3539
pubmed: 29467872
Biomed Pharmacother. 2017 Dec;96:634-641
pubmed: 29035829
Mol Cell. 2014 Mar 20;53(6):1005-19
pubmed: 24530304
FEBS Lett. 2017 Jan;591(2):382-392
pubmed: 28008602
PLoS One. 2013 Apr 23;8(4):e62334
pubmed: 23626803
Oncogene. 2016 May;35(21):2746-55
pubmed: 26364613
Onco Targets Ther. 2015 Sep 21;8:2657-64
pubmed: 26442763
Cell Physiol Biochem. 2018;50(1):136-149
pubmed: 30278449